PARP inhibitors in ovarian cancer.

Abstract	Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency. In this review, we provide a historical overview of PARPi use in EOC and discuss recent updates on overall survival data, highlighting their impact on regulatory approvals. We explore their potential as combination regimens with antiangiogenic and cell-cycle checkpoint inhibitors, as well as other small molecule inhibitors, to overcome resistance mechanisms and enhance therapeutic efficacy, providing a future perspective on the use of PARPis in EOC treatment.
Authors	Ian S Goldlust, Elena Guidice, Jung-Min Lee
Journal	Seminars in oncology (Semin Oncol) 2024 Feb-Apr Vol. 51 Issue 1-2 Pg. 45-57 ISSN: 1532-8708 [Electronic] United States
PMID	38262776 (Publication Type: Journal Article, Review)
Copyright	Published by Elsevier Inc.
Chemical References	Poly(ADP-ribose) Polymerase Inhibitors
Topics	Humans Female Poly(ADP-ribose) Polymerase Inhibitors (therapeutic use, pharmacology) Ovarian Neoplasms (drug therapy) Carcinoma, Ovarian Epithelial (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!